Tempus AI TEM stock forecast integrates consensus EPS estimates of $0.16 for the next quarter, a potential catalyst for a move above resistance at $37.50 if earnings beat the street by 10% or more. The general public, who are usually individual investors, hold a 11% stake in Tempus AI. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. This clearance marks a regulatory milestone for Tempus. The xR IVD is a next-generation sequencing, RNA-based diagnostic tool designed to analyze tumor tissue. Its primary function is to identify patients with solid malignant tumors who are most likely to respond to specific therapeutic treatments, thereby streamlining clinical trials for biopharmaceutical collaborators. Market breadth indicators reveal TEM outperforming sector averages by 4.6% over the last month. This divergence supports a forecast trajectory toward $40, provided momentum indicators remain positive.